Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.

Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB.

Lancet. 2003 Mar 1;361(9359):717-25. Erratum in: Lancet. 2005 Jul 16-22;366(9481):204.

PMID:
12620735
2.

Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.

Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group.

Lancet. 2014 Jan 18;383(9913):245-54. Review. Erratum in: Lancet. 2014 Jan 18;383(9913):218.

3.

Global burden of blood-pressure-related disease, 2001.

Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension.

Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8. Review.

PMID:
18456100
4.

Global burden of disease in young people aged 10-24 years: a systematic analysis.

Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD.

Lancet. 2011 Jun 18;377(9783):2093-102. doi: 10.1016/S0140-6736(11)60512-6. Epub 2011 Jun 7. Review. Erratum in: Lancet. 2011 Aug 6;378(9790):486.

PMID:
21652063
5.

Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.

Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJ, Vos T.

Lancet. 2013 Nov 9;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. Epub 2013 Aug 29. Review.

PMID:
23993281
6.

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T.

Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Review.

PMID:
23993280
7.
8.

Breastfeeding promotion and priority setting in health.

Horton S, Sanghvi T, Phillips M, Fiedler J, Perez-Escamilla R, Lutter C, Rivera A, Segall-Correa AM.

Health Policy Plan. 1996 Jun;11(2):156-68. Review.

9.
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

Optimizing chronic disease management mega-analysis: economic evaluation.

Path-Theta Collaboration.

Ont Health Technol Assess Ser. 2013 Sep 1;13(13):1-148. eCollection 2013. Review.

12.

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.

Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A.

Lancet. 2007 Dec 15;370(9604):2054-62. Epub 2007 Dec 11. Review.

PMID:
18063025
13.

Selected major risk factors and global and regional burden of disease.

Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group.

Lancet. 2002 Nov 2;360(9343):1347-60. Review.

PMID:
12423980
14.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

15.

Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.

Gaziano TA.

Heart. 2008 Feb;94(2):140-4. doi: 10.1136/hrt.2007.128785. Review.

PMID:
18195120
16.

Reducing population salt intake worldwide: from evidence to implementation.

He FJ, MacGregor GA.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):363-82. doi: 10.1016/j.pcad.2009.12.006. Review.

PMID:
20226955
17.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

18.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Diabetes Care. 2008 Aug;31(8):1686-96. doi: 10.2337/dc08-9022. Review.

19.

Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease.

Oldridge NB.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):130-9. doi: 10.1097/HJR.0b013e3282f19d42. Review.

PMID:
18391637
20.

Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use.

Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R.

Lancet. 2007 Dec 15;370(9604):2044-53. Epub 2007 Dec 11. Review. Erratum in: Lancet. 2007 Dec 15;370(9604):2004.

PMID:
18063027
Items per page

Supplemental Content

Write to the Help Desk